Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06708897 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
A Phase 1 study of CLL/SLL and CLL (Chronic Lymphocytic Leukemia), sponsored by Lomond Therapeutics Holdings.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 4
- Study locations
NCT06708897: Recruiting Phase 1 study of CLL/SLL and CLL (Chronic Lymphocytic Leukemia), sponsored by Lomond Therapeutics Holdings.
NCT06708897 is a Phase 1 study of CLL/SLL and CLL (Chronic Lymphocytic Leukemia) that is actively recruiting participants, run by Lomond Therapeutics Holdings. The registered enrollment target is 66 participants, below the 116-participant average among 6 other CLL/SLL trials with a reported enrollment target (43% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06708897, a Phase 1 study of CLL/SLL and CLL (Chronic Lymphocytic Leukemia), is actively recruiting participants, sponsored by Lomond Therapeutics Holdings.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
Primary Outcome
Number and percentage of participants with treatment-emergent adverse events, serious adverse events, clinically significant laboratory abnormalities, adverse events related to lonitoclax, and adverse events leading to treatment discontinuation. Adverse events are graded using NCI CTCAE Version 5.0.
Conditions Studied
Interventions
- DRUG ZE 50-0134
Study Locations (4)
Ohio
- University of Cincinnati - Cincinnati
- The Ohio State University - Columbus
Kentucky
- Norton Cancer Institute, St. Matthews Campus - Louisville
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What NCT06708897 shows while recruiting
NCT06708897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 116-participant average among 6 other CLL/SLL trials with a reported enrollment target (43% lower).
The record links to 3 conditions, with CLL/SLL appearing as the primary indexed condition, and to 1 intervention - of which ZE 50-0134 is the first listed.
NCT06708897 reports a single indexed study location in Ohio, Kentucky, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06708897 about?
NCT06708897 is a clinical study titled "A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas". This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.
What is the current status of trial NCT06708897?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2025-04-08. Estimated completion is 2028-04.
What conditions does trial NCT06708897 study?
This clinical trial studies the following conditions: CLL/SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma).
What interventions are being tested in trial NCT06708897?
The interventions under investigation include: ZE 50-0134 (DRUG).
Who is sponsoring clinical trial NCT06708897?
This trial is sponsored by Lomond Therapeutics Holdings, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06708897 being conducted?
This trial has 4 study locations across Kentucky, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CLL/SLL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
RECRUITING · Phase 1
-
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
RECRUITING · Phase 1
-
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Global Trial in APG2575 for Patients With CLL/SLL
RECRUITING · Phase 3
-
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
RECRUITING · Phase 2
-
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI